Performance
Revenue
$2,517mOperating profit
$282mCore¹ operating profit
$596mEBITDA
$680mCore EBITDA²
$694mProfit to shareholders
$188mCore profit to shareholders
$406mBasic earnings per share
84cCore basic earnings per share
181cDividend per share
56c- Core results are presented to show the underlying performance of the Group, excluding the exceptional items and other adjustments set out in Note 6 of the Group consolidated financial statements
- EBTIDA is earnings before interest, tax, depreciation, amortisation, assets write-down, impairment charges/reversals and unwinding of acquisition related inventory step-up. Core EBITDA is adjusted for exceptional items
Preliminary Results 2022
Key Highlights from Said Darwazah, Executive Chairman and Chief Executive Officer
Key highlights from Khalid Nabilsi, Chief Financial Officer
Key highlights from Riad Mishlawi, President, Injectables
Key highlights from Mazen Darwazah, Executive Vice Chairman and President MENA
Key highlights from Brian Hoffmann, President Generics
Four reasons to invest in Hikma
We have a strong business model with significant opportunities to further enhance our portfolio to drive growth and deliver value for shareholders.
1Solid platform for growth
- Broad portfolio of over 760 high-quality products across three businesses
- Agile supply chain, flexible manufacturing and leading technical capabilities
- Leading supplier of both generic injectable and non-injectable products in the US, the largest pharmaceutical market globally
- Leading market position in MENA (3rd largest pharmaceutical company by sales) and a growing presence in Europe
- Trusted partner known for our commitment to quality and reliability of supply
2Increasingly diverse portfolio and pipeline
- Growing presence in specialty and complex products, which offer less competition and potential for further margin growth
- Developing portfolio of biosimilars for the US and MENA markets
- Focus on higher-value therapeutic areas such as respiratory, CNS and oncology
- Continued investment in R&D, new partnerships, strategic acquisitions and geographic expansion into certain markets
3Excellent financial discipline with a strong balance sheet and robust cash generation
- Good cash flow generation, with $530 million operating cash flow in 2022 and low leverage of 1.5x net debt/core EBITDA
- Disciplined approach to cash management and acquisitions
- Strong balance sheet that provides financial flexibility to support future growth
4Proven track record of delivering value for shareholders and a clear vision for growth
- Group revenue CAGR of 5% and core EBITDA CAGR of 8% since 2017
- TSR of 196% over the last ten years
- Progressively increasing dividend
Understanding Hikma
Find out how our business model, strategy and established capabilities support our clear investment proposition
Investors calendar
3 August 2023
2023 Interim Results Announcement
2 November 2023
November Trading Update
Results and presentations
Regulatory news
News feed from the London Stock Exchange's Regulatory News Service.
Download our Corporate Factsheet
Information on the high standards of governance we’re committed to, our governance structure, Board, key committees, and remuneration policy.